Alpha-synuclein: The main actor at the first Patagonia Synuclein workshop
5 affiliations
- 1Max Planck Laboratory for Structural Biology, Chemistry and Molecular Biophysics (MPLbioR, UNR-MPINAT). Partner Laboratory of the Max Planck Institute for Multidisciplinary Sciences (MPINAT, MPG). Centro de Estudios Interdisciplinarios, Universidad Nacional de Rosario, Rosario, Argentina
- 2Department of NMR-based Structural Biology, Max Planck Institute for Multidisciplinary Sciences (MPINAT), Göttingen, Germany
- 3Faculdade de Medicina e Ciências Biomédicas, Algarve Biomedical Center, Algarve Biomedical Center Research Institute (ABC-Ri), Universidade do Algarve, Faro, Portugal
- 4Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, Göttingen, Germany
- 5Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK
Abstract
The accumulation of aggregated alpha-synuclein (aSyn) in the brain is one of the defining pathological features in Parkinson's Disease, Parkinson's Disease with Dementia, Lewy Body Dementia, and Multiple System Atrophy. For this reason, this group of disorders is collectively known as synucleinopathies. The identification of autosomal dominant mutations in the gene encoding aSyn (SNCA) in hereditary forms of disease further supports a central role for this protein in pathogenesis. The Synuclein Workshop was held for the first time in 2025 and is intended to be organized regularly every 2 years in countries of Latin America. The purpose of this series of workshops is to bring together leading experts in the field of synucleinopathies in a part of the world that is known for a strong tradition in the field, and to enable early career researchers to engage with and learn from other renowned experts, with the overall goal of discussing and advancing research in the field. In 2025, the Synuclein Workshop took place in Villa La Angostura, a city located in the province of Neuquén, Argentina. The meeting, entitled “The Patagonia Synuclein Workshop 2025”, brought together 100 scientists studying both clinical and biomolecular aspects of synucleinopathies. The meeting covered many of the open questions in the field, in a format that promoted and encouraged open and unbiased discussions between the participants, and underscored the need for additional research that, hopefully, will lead to the development of new diagnostic tools and therapeutic strategies. Here, we provide a summary of the main topics discussed in the meeting, and highlight what is the current knowledge in the field, what we still do not know, and the future directions necessary for achieving the ultimate goal of the community: to offer better options to patients, families, and care-givers.
Related
- The Sulfate-Reducing Bacteria Hypothesis in Parkinson’s Disease: From Desulfovibrio-Derived Hydrogen Sulfide to Alpha-Synuclein Aggregation
- Direct-to-biology approach for the selective identification of ligands for alpha-synuclein aggregates
- From dosage alteration to amplification strategies: mechanistically defined alpha-synuclein mouse models for Parkinson's disease therapy development.
- Path to Prevention Platform Trial in Early-Stage Neuronal Alpha-Synuclein Disease: Study Design
- Cerebrospinal fluid alpha-synuclein seed amplification assay positivity identifies a prognostically distinct subgroup in amyotrophic lateral sclerosis
BibTeX
@article{outon2026alphasynuclein,
title = {{Alpha-synuclein: The main actor at the first Patagonia Synuclein workshop}},
author = {Claudio O. Fernández Outón and Phelippe Do Carmo Gonçalves and Irina Fernández and Tiago F. Outeiro},
journal = {Journal of Parkinson's Disease},
year = {2026},
month = oct,
doi = {10.1177/1877718x261494920},
url = {https://doi.org/10.1177/1877718x261494920},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Alpha-synuclein: The main actor at the first Patagonia Synuclein workshop
AU - Claudio O. Fernández Outón
AU - Phelippe Do Carmo Gonçalves
AU - Irina Fernández
AU - Tiago F. Outeiro
PY - 2026
DA - 2026/10/30
JO - Journal of Parkinson's Disease
DO - 10.1177/1877718x261494920
UR - https://doi.org/10.1177/1877718x261494920
AB - The accumulation of aggregated alpha-synuclein (aSyn) in the brain is one of the defining pathological features in Parkinson's Disease, Parkinson's Disease with Dementia, Lewy Body Dementia, and Multiple System Atrophy. For this reason, this group of disorders is collectively known as synucleinopathies. The identification of autosomal dominant mutations in the gene encoding aSyn (SNCA) in hereditary forms of disease further supports a central role for this protein in pathogenesis. The Synuclein Workshop was held for the first time in 2025 and is intended to be organized regularly every 2 years in countries of Latin America. The purpose of this series of workshops is to bring together leading experts in the field of synucleinopathies in a part of the world that is known for a strong tradition in the field, and to enable early career researchers to engage with and learn from other renowned experts, with the overall goal of discussing and advancing research in the field. In 2025, the Synuclein Workshop took place in Villa La Angostura, a city located in the province of Neuquén, Argentina. The meeting, entitled “The Patagonia Synuclein Workshop 2025”, brought together 100 scientists studying both clinical and biomolecular aspects of synucleinopathies. The meeting covered many of the open questions in the field, in a format that promoted and encouraged open and unbiased discussions between the participants, and underscored the need for additional research that, hopefully, will lead to the development of new diagnostic tools and therapeutic strategies. Here, we provide a summary of the main topics discussed in the meeting, and highlight what is the current knowledge in the field, what we still do not know, and the future directions necessary for achieving the ultimate goal of the community: to offer better options to patients, families, and care-givers.
SN - 1877-7171
SN - 1877-718X
ER -